Syntax Bio funding boost puts pancreatic beta cell therapy closer to preclinical test
Find out how Syntax Bio’s expanded Series A could shape Cellgorithm-based beta cell therapy for type 1 diabetes.
Find out how Syntax Bio’s expanded Series A could shape Cellgorithm-based beta cell therapy for type 1 diabetes.
How NewcelX Ltd. is advancing NCEL-101 toward a functional diabetes cure through durable islet graft survival and immune protection strategies.
Matricelf plans a subsidiary to commercialize its Parkinson’s therapy platform. Discover what this move signals for regenerative medicine and neurology innovation.
ElpasBio partners with Fosun Kairos to commercialize AlloJoin stem cell therapy for KOA in China. Find out what this deal means for the cell therapy market.
Medipost secures $140M to fund a pivotal U.S. Phase III trial in osteoarthritis. See how this could reshape the future of scalable stem cell therapies.